BioNexus Gene Lab director receives stock award

Low Jook Yuen reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Low Jook Yuen reported acquisition or exercise transactions in this Form 4 filing.

BioNexus Gene Lab Corp director Low Jook Yuen received an equity compensation grant of 16,129 shares of common stock on August 13, 2026. The fully vested Other Stock-Based Award was granted for completed services under the company’s 2025 Equity Incentive Plan, for no cash consideration, and valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this award, Low Jook Yuen holds 17,390 shares of BioNexus Gene Lab Corp common stock directly.

Insider Trade Summary

Grant/Award: 16,129 shares

Grant/Award 1 txn

Insider Low Jook Yuen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	16,129	--	--

Holdings After Transaction: Common Stock — 17,390 shares (Direct)

Footnotes (1)

1. F1. Represents a fully vested Other Stock-Based Award of 16,129 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

Key Figures

Shares granted: 16,129 shares of common stock Post-transaction holdings: 17,390 shares of common stock Plan valuation price: $1.55 per share +1 more

4 metrics

Shares granted 16,129 shares of common stock Fully vested Other Stock-Based Award granted on August 13, 2026

Post-transaction holdings 17,390 shares of common stock Direct holdings of Low Jook Yuen after the award

Plan valuation price $1.55 per share Nasdaq closing price on August 12, 2026 used to value the award

Award cash consideration No cash consideration Award granted for completed services under 2025 Equity Incentive Plan

Key Terms

Other Stock-Based Award, 2025 Equity Incentive Plan, no par value, Nasdaq closing price

4 terms

Other Stock-Based Award financial

"Represents a fully vested Other Stock-Based Award of 16,129 shares of common stock"

2025 Equity Incentive Plan financial

"granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan"

no par value financial

"16,129 shares of common stock, no par value, granted on August 13, 2026"

Shares described as "no par value" are equity securities issued without a fixed face amount written into the corporate charter; their legal capital is not tied to a specific per-share number and the company may record proceeds differently than for par-value shares. This matters to investors because it affects how a company records equity, sets minimum legal capital, and handles bookkeeping for issuances, dividends and splits—similar to buying slices of a pie where the slice has no printed sticker price and market forces determine worth.

Nasdaq closing price financial

"valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen report in this Form 4?

Low Jook Yuen reported receiving a grant of 16,129 shares of BioNexus Gene Lab Corp common stock as a fully vested Other Stock-Based Award for completed services under the 2025 Equity Incentive Plan.

How many BGLC shares does Low Jook Yuen hold after the reported transaction?

After the grant, Low Jook Yuen directly holds 17,390 shares of BioNexus Gene Lab Corp common stock. This reflects the newly awarded 16,129 shares added to the director’s prior holdings.

What was the valuation used for the BGLC stock award to Low Jook Yuen?

The 16,129-share award was valued for plan purposes at $1.55 per share, equal to the Nasdaq closing price of BioNexus Gene Lab Corp common stock on August 12, 2026, immediately preceding the August 13, 2026 grant.

Was there any cash consideration for the BGLC stock grant to Low Jook Yuen?

No. The filing states the 16,129-share award was granted for completed services and for no cash consideration, meaning it represents non-cash equity compensation under the 2025 Equity Incentive Plan.

Was the BGLC stock award to Low Jook Yuen subject to vesting?

The award is described as a fully vested Other Stock-Based Award of 16,129 shares. This indicates the shares were fully vested at the time of grant, rather than vesting over a future schedule.

Was the BGLC Form 4 transaction under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and the footnote describes a compensation grant, so the reported acquisition is an equity award, not a trade pursuant to a 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:15 PM Accepted by SEC EDGAR 08/14/2026 - 05:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Low Jook Yuen

(Last) (First) (Middle)

NO 6

TINGKAT PASIR PUTEH 4

(Street)

TAMAN YIK SANG IPOH 31650

(City) (State) (Zip)

MALAYSIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNexus Gene Lab Corp [ BGLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		A		16,129	A	(1)	17,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a fully vested Other Stock-Based Award of 16,129 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

	/s/ Jook Yuen Low	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)